title: Two birds with one stone: dual p110δ and p110γ inhibition.
abstract: In this issue of Chemistry & Biology, Winkler and colleagues describe the discovery and preclinical development of IPI-145, a new inhibitor of the phosphoinositide 3-kinase (PI3K) isoforms p110δ and p110γ that have entered clinical trials.
authors.affiliation: Laboratory of Lymphocyte Signaling and Development, The Babraham Institute, Cambridge CB22 3AT, UK. Electronic address: klaus.okkenhaug@babraham.ac.uk.
authors.forename: Klaus
authors.initials: K
authors.lastname: Okkenhaug
mesh_terms: D000818:Animals; D001168:Arthritis / Q000188:drug therapy*; D001249:Asthma / Q000188:drug therapy*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011687:Purines / Q000494:pharmacology*
chemical_list: D007546:Isoquinolines; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011687:Purines; C586691:duvelisib